Key Takeaways
- FDA advisers unanimously back Eli Lilly’s Alzheimer’s drug, donanemab.
- Donanemab shows a 35% slower decline in early-stage Alzheimer’s patients.
- Final FDA approval decision expected later this year.
What Happened?
Eli Lilly’s new Alzheimer’s drug, donanemab, received unanimous backing from FDA advisers on June 10, 2024. The advisers believe the drug’s benefits in slowing cognitive decline outweigh its risks, including brain swelling and bleeding.
If approved, donanemab will be the second drug in the U.S. proven to slow Alzheimer’s progression. In a 1,700-patient study, those on donanemab declined 35% slower than those on a placebo. The FDA will make the final approval decision later this year.
Why It Matters?
This endorsement marks a significant milestone for Alzheimer’s treatment, providing new hope for millions affected by the disease. Donanemab’s ability to slow cognitive decline could offer patients and their families valuable extra months of mental clarity.
This could impact Eli Lilly’s stock positively, given the high demand for effective Alzheimer’s treatments. However, the necessity of monitoring for side effects like brain swelling and bleeding remains a concern.
What’s Next?
The FDA will decide on final approval later this year. If approved, donanemab could become widely available, potentially transforming Alzheimer’s care. Investors should watch for updates on the FDA’s decision and any new data on long-term safety and efficacy.
Additionally, monitoring Eli Lilly’s market performance and comparing it with competitors like Eisai, who also have similar treatments, will be crucial.
